Cover Image
市場調查報告書

PharmaPoint:偏頭痛 - 全球醫藥品的預測與市場分析

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 305466
出版日期 內容資訊 英文 278 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:偏頭痛 - 全球醫藥品的預測與市場分析 PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023
出版日期: 2014年03月31日 內容資訊: 英文 278 Pages
簡介

偏頭痛治療藥市場由於學名藥而呈現飽合狀態,除了慢性偏頭痛治療藥Botox以外,已上市的其他品牌藥預測將在今後數年漸漸失去獨佔性。但既有產品的劑形改變、新類治療藥開始銷售,一般預測偏頭痛治療藥市場到2023年前將以CAGR3.6%的速度擴大到37億美金的規模。

本報告提供全球偏頭痛治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預後
  • 症狀
    • 前驅症狀階段
    • 徵兆階段
    • 頭痛階段
    • 以後症狀的階段

第4章 病因

  • 疾病的背景
  • 與風險要素並存疾病
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
  • 流行病學的預測
    • 偏頭痛的整體患病者
    • 各年齡的整體患病者
    • 性別的整體患病者
    • 已調整年齡的整體患病人數
    • 處於徵兆階段的偏頭痛和沒有的偏頭痛整體患病人數
  • 議論
  • 第5章 疾病的管理
  • 治療概要
    • 對嚴重的偏頭痛的治療
    • 預防
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介-領導品牌
    • Triptans
    • Imitrex (sumatriptan)
    • Zomig (zolmitriptan)
    • Amerge (naratriptan)
    • Maxalt (rizatriptan)
    • Axert (almotriptan)
    • Frova (frovatriptan)
    • Relpax (eletriptan)
    • Sumavel DosePro (sumatriptan)
    • Ergot Alkaloids
    • Beta Blockers
    • Anti-Epileptics
    • Antidepressants
    • Calcium Channel Antagonists
    • Botox (onabotulinum toxin A)

第7章 機會及未滿足需求

  • 概要
  • 未滿足需求的差距分析

第8章 開發平台評估

  • 概要
  • 臨床試驗的製圖(定位)
  • 階段及臨床各狀況:臨床試驗
  • 臨床開發中的潛力藥物

第9章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • GlaxoSmithKline
    • AstraZeneca
    • Merck
    • Vernalis
    • Almirall
    • Pfizer
    • Zogenix
    • NuPathe
    • Allergan
    • RedHill Biopharma
    • OptiNose
    • CoLucid Pharmaceuticals
    • SUDA
    • Revance Therapeutics
    • NeurAxon

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第11章 附錄

圖表

目錄
Product Code: GDHC106PIDR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Highlights

Key Questions Answered

  • The migraine market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the migraine market?
  • The late-stage migraine pipeline is filled with therapies with diverse formulations and routes of administration. Which drug will have a significant impact on the migraine market. Which of these drugs will have the highest CAGR, and why?
  • The migraine market is currently dominated by generic drugs. How will the introduction of combinations of device and drugs, and new classes of therapies change the treatment landscape once reimbursement is not a problem anymore? How will the drug treatment rates change over the next ten years? What are the key drivers and barriers to this change?

Key Findings

  • The main driver of the expansion of the migraine market will be the continuous use of Botox for chronic migraine. The introduction of reformulations of mature products as well as new classes of therapies will further increase the market size.
  • The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for migraine, which have resulted in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period.
  • The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively.

Scope

  • Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized migraine therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2023.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the migraine therapeutics market.
  • Pipeline analysis: focus on the seven late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global migraine therapeutics market from 2012-2017.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. Female sex and family history are interrelated risk factors of migraine
    • 4.2.2. People with migraine also suffer from several comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast methodology
    • 4.4.1. Sources used
    • 4.4.2. Sources not used
    • 4.4.3. Forecast assumptions and methods
  • 4.5. Epidemiological Forecast for Migraine (2013-2023)
    • 4.5.1. Total Prevalent Cases of Migraine
    • 4.5.2. Age-Specific Total Prevalent Cases of Migraine
    • 4.5.3. Sex-Specific Total Prevalent Cases of Migraine
    • 4.5.4. Age-Standardized Total Prevalence of Migraine
    • 4.5.5. Total Prevalent Cases of Migraine with Aura and Migraine without Aura
  • 4.6. Discussion
    • 4.6.1. Conclusions on Epidemiological Trends
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Treatment Overview
    • 5.1.1. Acute Migraine Treatment
    • 5.1.2. Preventive Migraine Treatment
  • 5.2. US
    • 5.2.1. Diagnosis
    • 5.2.2. Clinical Practice
  • 5.3. France
    • 5.3.1. Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. UK
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. Japan
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice

6. Competitive Assessment

  • 6.1 Overview
  • 6.2 Strategic Competitor Assessment
  • 6.3 Product Profiles- Major Brands
    • 6.3.1 Triptans
    • 6.3.2 Imitrex (sumatriptan)
    • 6.3.3 Zomig (zolmitriptan)
    • 6.3.4 Amerge (naratriptan)
    • 6.3.5 Maxalt (rizatriptan)
    • 6.3.6 Axert (almotriptan)
    • 6.3.7 Frova (frovatriptan)
    • 6.3.8 Relpax (eletriptan)
    • 6.3.9 Sumavel DosePro (sumatriptan)
    • 6.3.10 Ergot Alkaloids
    • 6.3.11 Beta Blockers
    • 6.3.12 Anti-Epileptics
    • 6.3.13 Antidepressants
    • 6.3.14 Calcium Channel Antagonists
    • 6.3.15 Botox (onabotulinum toxin A)

7. Opportunity and Unmet Need

  • 7.1 Overview
    • 7.1.1 A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
    • 7.1.2 Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
    • 7.1.3 Lack of Diagnostic Tools Causes Misdiagnosis
    • 7.1.4 Physician Education
    • 7.1.5 Effective and Well-Tolerated Prophylactic Therapies
  • 7.2 Unmet Needs Gap Analysis
    • 7.2.1 Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
    • 7.2.2 Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
    • 7.2.3 Physician Education
    • 7.2.4 Diagnostic Tools

8. Pipeline Assessment

  • 8.1 Overview
  • 8.2 Clinical Trial Mapping
    • 8.2.1 Clinical Trials by Country
  • 8.3 Clinical Trials by Phase and Trial status
  • 8.4 Promising drugs in clinical development
    • 8.4.1 Zecuity
    • 8.4.2 Levadex
    • 8.4.3 RHB-103
    • 8.4.4 AVP-825
    • 8.4.5 Lasmiditan
    • 8.4.6 MK-1602
    • 8.4.7 SUD-001
    • 8.4.8 RT-001
    • 8.4.9 NXN-188

9. Current and Future Players

  • 9.1 Overview
  • 9.2 Trends in Corporate Strategy
  • 9.3 Company Profiles
    • 9.3.1 GlaxoSmithKline
    • 9.3.2 AstraZeneca
    • 9.3.3 Merck
    • 9.3.4 Vernalis
    • 9.3.5 Almirall
    • 9.3.6 Pfizer
    • 9.3.7 Zogenix
    • 9.3.8 NuPathe
    • 9.3.9 Allergan
    • 9.3.10 RedHill Biopharma
    • 9.3.11 OptiNose
    • 9.3.12 CoLucid Pharmaceuticals
    • 9.3.13 SUDA
    • 9.3.14 Revance Therapeutics
    • 9.3.15 NeurAxon

10. Market Outlook

  • 10.1 Global Markets
    • 10.1.1 Forecast
    • 10.1.2 Drivers and Barriers - Global Issues
  • 10.2 US
    • 10.2.1 Forecast
    • 10.2.2 Key Events
    • 10.2.3 Drivers and Barriers
  • 10.3 France
    • 10.3.1 Forecast
    • 10.3.2 Key Events
    • 10.3.3 Driver and Barriers
  • 10.4 Germany
    • 10.4.1 Forecast
    • 10.4.2 Key Events
    • 10.4.3 Driver and Barriers
  • 10.5 Italy
    • 10.5.1 Forecast
    • 10.5.2 Key Events
    • 10.5.3 Driver and Barriers
  • 10.6 Spain
    • 10.6.1 Forecast
    • 10.6.2 Key Events
    • 10.6.3 Driver and Barriers
  • 10.7 United Kingdom
    • 10.7.1 Forecast
    • 10.7.2 Key Events
    • 10.7.3 Driver and Barriers
  • 10.8 Japan
    • 10.8.1 Forecast
    • 10.8.2 Key Events
    • 10.8.3 Driver and Barriers

11. Appendix

  • 11.1 Bibliography
  • 11.2 Abbreviations
  • 11.3 Methodology
  • 11.4 Forecasting Methodology
    • 11.4.1 Diagnosed Migraine Patients
    • 11.4.2 Percent Drug-treated Patients
    • 11.4.3 Drugs Included in Each Therapeutic Class
    • 11.4.4 Launch and Patent Expiry Dates
    • 11.4.5 General Pricing Assumptions
    • 11.4.6 Individual Drug Assumptions
    • 11.4.7 Generic Erosion
    • 11.4.8 Pricing of Pipeline agents
  • 11.5 Physicians and Specialists Included in this Study
  • 11.6 Survey of Prescribing Physicians
  • 11.7 About the Authors
    • 11.7.1 Author
    • 11.7.2 Reviewer
    • 11.7.3 Epidemiologist
    • 11.7.4 Global Head of Healthcare
  • 11.8 About GlobalData
  • 11.9 Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Risk Factors and Comorbidities for Migraine
  • Table 5: Prevalence of the Most Frequent Comorbidities in People with and without Migraine, Ages ≥18 Years, Both Sexes
  • Table 6: One-Year Total Prevalence (%) of Migraine in the 5EU
  • Table 7: Lifetime Total Prevalence (%) of Migraine in the 3EU
  • Table 8: Criteria Proposed by the Second Edition of the International Classification of Headache Disorders (ICHD-2)
  • Table 9: Epidemiological Sources of Total Prevalence Data Used in the Analysis for Migraine and its Subtypes (Migraine with Aura and Migraine without Aura)
  • Table 10: 7MM, Total Prevalent Cases of Migraine, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Table 11: 7MM, Total Prevalent Cases of Migraine, by Age, Both Sexes, N, (Row %), 2013
  • Table 12: 7MM, Total Prevalent Cases of Migraine, by Sex, Ages ≥18 years, N (Row %), 2013
  • Table 13: 7MM, Total Prevalent Cases of Migraine with Aura and Migraine without Aura, Ages ≥18 Years, Both Sexes, N, Row (%), 2013
  • Table 14: Treatment Guidelines for Migraine
  • Table 15: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 16: Product Profile - Triptans
  • Table 17: Triptans SWOT Analysis, 2013
  • Table 18: Global Sales Forecasts ($m) for Imitrex, 2012-2023
  • Table 19: Global Sales Forecasts ($m) for Zomig, 2012-2023
  • Table 20: Global Sales Forecasts ($m) for Amerge, 2012-2023
  • Table 21: Global Sales Forecasts ($m) for Maxalt, 2012-2023
  • Table 22: Global Sales Forecasts ($m) for Axert, 2012-2023
  • Table 23: Global Sales Forecasts ($m) for Frova, 2012-2023
  • Table 24: Global Sales Forecasts ($m) for Relpax, 2012-2023
  • Table 25: Product Profile - Sumavel DosePro
  • Table 26: Sumavel DosePro SWOT Analysis, 2013
  • Table 27: Global Sales Forecasts ($m) for Sumavel DosePro, 2012-2023
  • Table 28: Product Profile - Ergot Alkaloids
  • Table 29: Ergot Alkaloids SWOT Analysis, 2013
  • Table 30: Global Sales Forecasts ($m) for Ergot Alkaloids, 2012-2023
  • Table 31: Product Profile - Beta Blockers
  • Table 32: Beta Blockers SWOT Analysis, 2013
  • Table 33: Global Sales Forecasts ($m) for Beta Blockers, 2012-2023
  • Table 34: Product Profile - Anti-Epileptics
  • Table 35: Anti-Epileptics SWOT Analysis, 2013
  • Table 36: Global Sales Forecasts ($m) for Anti-Epileptics, 2012-2023
  • Table 37: Product Profile - Antidepressants
  • Table 38: Antidepressants SWOT Analysis, 2013
  • Table 39: Global Sales Forecasts ($m) for Antidepressants, 2012-2023
  • Table 40: Product Profile-Calcium Channel Antagonists
  • Table 41: Calcium Channel Antagonists SWOT Analysis, 2013
  • Table 42: Global Sales Forecasts ($m) for Calcium Channel Antagonists, 2012-2023
  • Table 43: Product Profile - Botox
  • Table 44: Botox SWOT Analysis, 2013
  • Table 45: Global Sales Forecasts ($m) for Botox, 2012-2023
  • Table 46: Overall Unmet Needs - Current Level of Attainment
  • Table 47: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 48: Migraine - Clinical Trials by Phase and Status, 2013
  • Table 49: Migraine - Promising Late-Stage Pipeline, 2013
  • Table 50: Comparison of Therapeutic Classes in Development for Migraine, 2013
  • Table 51: Product Profile - Zecuity
  • Table 52: Zecuity SWOT Analysis, 2013
  • Table 53: Global Sales Forecasts ($m) for Zecuity, 2012-2023
  • Table 54: Product Profile - Levadex
  • Table 55: Levadex SWOT Analysis, 2013
  • Table 56: Global Sales Forecasts ($m) for Levadex, 2012-2023
  • Table 57: Product Profile - RHB-103
  • Table 58: RHB-103 SWOT Analysis, 2013
  • Table 59: Global Sales Forecasts ($m) for RHB-103, 2012-2023
  • Table 60: Product Profile - AVP-825
  • Table 61: AVP-825 SWOT Analysis, 2013
  • Table 62: Global Sales Forecasts ($m) for AVP-825, 2012-2023
  • Table 63: Product Profile - Lasmiditan
  • Table 64: Lasmiditan SWOT Analysis, 2013
  • Table 65: Global Sales Forecasts ($m) for lasmiditan, 2012-2023
  • Table 66: Product Profile - MK-1602
  • Table 67: MK-1602 SWOT Analysis, 2013
  • Table 68: Global Sales Forecasts ($m) for MK-1602, 2012-2023
  • Table 69: Product Profile - SUD-001
  • Table 70: SUD-001 SWOT Analysis, 2013
  • Table 71: Global Sales Forecasts ($m) for SUD-001, 2012-2023
  • Table 72: Product Profile - RT-001
  • Table 73: RT-001 SWOT Analysis, 2013
  • Table 74: Product Profile - NXN-188
  • Table 75: NXN-188 SWOT Analysis, 2013
  • Table 76: Key Companies in the Migraine Market, 2013
  • Table 77: GSK's Migraine Portfolio Assessment, 2013
  • Table 78: GSK SWOT Analysis, 2013
  • Table 79: AstraZeneca's Migraine Portfolio Assessment, 2013
  • Table 80: AstraZeneca SWOT Analysis, 2013
  • Table 81: Merck's Migraine Portfolio Assessment, 2013
  • Table 82: Merck SWOT Analysis, 2013
  • Table 83: Vernalis' Migraine Portfolio Assessment, 2013
  • Table 84: Vernalis SWOT Analysis, 2013
  • Table 85: Almirall's Migraine Portfolio Assessment, 2013
  • Table 86: Almirall SWOT Analysis, 2013
  • Table 87: Pfizer's Migraine Portfolio Assessment, 2013
  • Table 88: Pfizer SWOT Analysis, 2013
  • Table 89: Zogenix's Migraine Portfolio Assessment, 2013
  • Table 90: Zogenix SWOT Analysis, 2013
  • Table 91: NuPathe's Migraine Portfolio Assessment, 2013
  • Table 92: NuPathe SWOT Analysis, 2013
  • Table 93: Allergan's Migraine Portfolio Assessment, 2013
  • Table 94: Allergan SWOT Analysis, 2013
  • Table 95: RedHill's Migraine Portfolio Assessment, 2013
  • Table 96: RedHill SWOT Analysis, 2013
  • Table 97: OptiNose's Migraine Portfolio Assessment, 2013
  • Table 98: OptiNose SWOT Analysis, 2013
  • Table 99: CoLucid Pharmaceuticals' Migraine Portfolio Assessment, 2013
  • Table 100: CoLucid Pharmaceuticals SWOT Analysis, 2013
  • Table 101: SUDA's Migraine Portfolio Assessment, 2013
  • Table 102: SUDA SWOT Analysis, 2013
  • Table 103: Revance Therapeutics' Migraine Portfolio Assessment, 2013
  • Table 104: Revance Therapeutics SWOT Analysis, 2013
  • Table 105: NeurAxon's Migraine Portfolio Assessment, 2013
  • Table 106: NeurAxon SWOT Analysis, 2013
  • Table 107: Global Sales Forecasts ($m) for Migraine, 2012-2023
  • Table 108: Migraine Market - Drivers and Barriers, 2012-2023
  • Table 109: Sales Forecasts ($m) for Migraine in the US, 2012-2023
  • Table 110: Key Events Impacting Sales for Migraine in the US, 2012-2023
  • Table 111: US Migraine Market - Drivers and Barriers, 2012-2023
  • Table 112: Sales Forecasts ($m) for Migraine in France, 2012-2023
  • Table 113: Key Events Impacting Sales for Migraine in France, 2012-2023
  • Table 114: Migraine Market - Drivers and Barriers, 2012-2023
  • Table 115: Sales Forecasts ($m) for Migraine in Germany, 2012-2023
  • Table 116: Key Events Impacting Sales for Migraine in Germany, 2012-2023
  • Table 117: German Migraine Market - Drivers and Barriers, 2012-2023
  • Table 118: Sales Forecasts ($m) for Migraine in Italy, 2012-2023
  • Table 119: Key Events Impacting Sales for Migraine in Italy, 2012-2023
  • Table 120: Italian Migraine Market - Drivers and Barriers, 2012-2023
  • Table 121: Sales Forecasts ($m) for Migraine in Spain, 2012-2023
  • Table 122: Key Events Impacting Sales for Migraine in Spain, 2012-2023
  • Table 123: Spanish Migraine Market - Drivers and Barriers, 2012-2023
  • Table 124: Sales Forecasts ($m) for Migraine in the UK, 2012-2023
  • Table 125: Key Events Impacting Sales for Migraine in the UK, 2012-2023
  • Table 126: UK Migraine Market - Drivers and Barriers, 2012-2023
  • Table 127: Sales Forecasts ($m) for Migraine in Japan, 2012-2023
  • Table 128: Key Events Impacting Sales for Migraine in Japan, 2012-2023
  • Table 129: Japanese Migraine Market - Drivers and Barriers, 2012-2023
  • Table 130: Key Launch or Approval Dates
  • Table 131: Key Patent Expiries
  • Table 132: Physicians Surveyed, By Country

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of Migraine, Ages ≥18 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Total Prevalent Cases of Migraine, by Age, Both Sexes, N, 2013
  • Figure 3: 7MM, Total Prevalent Cases of Migraine, by Sex, Ages ≥18 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Total Prevalence of Migraine, Ages ≥18 Years, 2013
  • Figure 5: 7MM, Total Prevalent Cases of Migraine with Aura and Migraine without Aura, Ages ≥18 Years, Both Sexes, N, Row (%), 2013
  • Figure 6: Migraine Treatment Algorithm in the 7MM
  • Figure 7: Migraine Therapeutics - Clinical Trials by Country, 2012
  • Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in Migraine, 2012-2023
  • Figure 9: Company Portfolio Gap Analysis in Migraine, 2012-2023
  • Figure 10: Global Sales for Migraine by Region, 2012-2023
  • Figure 11: Sales for Migraine in the US by Drug Class, 2012-2023
  • Figure 12: Sales for Migraine in France by Drug Class, 2012-2023
  • Figure 13: Sales for Migraine in Germany by Drug Class, 2012-2023
  • Figure 14: Sales for Migraine in Italy by Drug Class, 2012-2023
  • Figure 15: Sales for Migraine in Spain by Drug Class, 2012-2023
  • Figure 16: Sales for Migraine in the UK by Drug Class, 2012-2023
  • Figure 17: Sales for Migraine in Japan by Drug Class, 2012-2023
Back to Top